Περίληψη:
Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N=33) are significantly lower (p<0.01) than those of cognitively healthy elderly individuals without AD (N=39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate. © 2019 - IOS Press and the authors. All rights reserved.
Συγγραφείς:
Alexopoulos, P.
Thierjung, N.
Economou, P.
Werle, L.
Buhl, F.
Kagerbauer, S.
Papanastasiou, A.D.
Grimmer, T.
Gourzis, P.
Berthele, A.
Hemmer, B.
Kübler, H.
Martin, J.
Politis, A.
Perneczky, R.
Λέξεις-κλειδιά:
abetappbeta protein; amyloid beta protein; apolipoprotein E4; unclassified drug; amyloid precursor protein; biological marker; tau protein, adult; aged; Alzheimer disease; Article; cerebrospinal fluid; cerebrospinal fluid level; clinical article; cost effectiveness analysis; daily life activity; dementia; diagnosis related group; disease marker; elective surgery; enzyme linked immunosorbent assay; female; genotype; human; limit of detection; male; Mini Mental State Examination; peripheral nervous system; priority journal; procedures; protein blood level; spinal anesthesia; urologic surgery; Alzheimer disease; blood; dementia; middle aged, Aged; Alzheimer Disease; Amyloid beta-Protein Precursor; Biomarkers; Dementia; Female; Humans; Male; Middle Aged; tau Proteins
